Ardelyx Inc. (ARDX)
ARDX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/0001437402-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ARDX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001437402 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $407.3M |
| Net income | -$61.6M |
| Operating income | -$41.0M |
| Net margin | -15.1% |
| Operating margin | -10.1% |
| Revenue growth | +22.1% |
| Cash | $68.0M |
| Total assets | $501.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $46.3M cash; operating cash flow -$3.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 251,372,553 (2026-10-27); 242,974,306 a year earlier; 232,137,709 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.9M, sold $4.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $127.7M | -$737K | $2.2M | $46.3M | $252.4M | $468.2M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $120.9M | -$16.7M | -$6.4M | $97.2M | $251.8M | $450.9M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $94.5M | -$37.6M | -$32.2M | $31.2M | $203.5M | $427.7M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $125.2M | -$407K | $21.0M | $68.0M | $202.8M | $407.3M | 10-K 2026-02-19 |
| Q3 2025 2025-09-30 | $110.3M | -$969K | $365K | $42.7M | $202.1M | $398.2M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $97.7M | -$19.1M | -$25.3M | $90.0M | $201.4M | $386.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $74.1M | -$41.1M | -$38.5M | $30.8M | $151.3M | $361.7M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $116.1M | $4.6M | $9.8M | $64.9M | $150.9M | $333.6M | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-11-03 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-05-26 |
Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.3% |
| 1 month | -1.0% |
| 3 months | -21.0% |
| Year to date | -47.0% |
| 1 year | -47.0% |
| From 52-week high | -61.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LXRX | Lexicon Pharmaceuticals Inc. | $1.75 | -2.23% | $779.2M |
| ORIC | Oric Pharmaceuticals Inc. | $7.52 | -4.33% | $779.5M |
| OBX | Obsidian Therapeutics Inc. | $12.36 | -1.59% | $763.5M |
| IVA | Inventiva S.A. American Depository Shares | $3.32 | -9.78% | $784.5M |
| COLL | Collegium Pharmaceutical Inc. | $25.43 | +0.43% | $790.2M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier